Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupunfitICD10C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-MeSHLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Mantle-CellSequenceGADOLIN: OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1 (PID710) -|- C2-6 (PID724) -|- maint. (PID725)GAUSS: OBIN1000, B-NHL, Ind. (PID2340) -|- OBIN1000, B-NHL, maint. (PID2341)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)ChemotherapyChemo-substanceAcalabrutinibBendamustineBortezomibCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineBortezomibCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineBortezomibCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineBortezomibCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibNo. Substances1236 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneNo. Substances124679Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceSalvageTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlAtrial FibrillationBleedingCardiotoxicityDiarrheaDysphagiaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypertensionHyponatremiaHypotensionIncrease AminotransferasesInfectionsInfusion ReactionNeuropathyNeutropeniaPneumoniaPneumonitisPruritusPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorArdeshna KMFriedberg JWGopal AKKirschey SOpat SRobinson KSRummel MJSehn LSehn LHStrati PTuscano JMDiseaseCD20-positives indolentes B-Non-Hodgkin-Lymphom, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2Foll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Foll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätIndolente B-Non-Hodgkin-Lymphome und Mantelzelllymphom, mind. 1 VortherapieMarginalzonenlymphom, therapierefraktär oder rezidiviert, mindestens eine Vortherapie, ECOG 0-2MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieNon-Hodgkin Lymphom, low-grade, nicht-aggressiv, Stadium III-IVRefraktäres oder rezidiviertes Marginalzonenlymphom, Zweitlinie, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Rituximab refraktäre indolente B-NHL, ECOG 0-2OriginBritish Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada, GADOLIN trialBritish National Lymphoma Investigation, CRC and UCL Cancer Trials Centre, London, UKCentre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, GAUSS StudyDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USAJames P. Wilmot Cancer Center, University of Rochester, RochesterMonash University, Clayton, Victoria, Australia, MAGNOLIA trialQE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaStudy Group indolent Lymphomas (StiL)The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, ACE-LY-003UC Davis Cancer Center, Sacramento, USAProtocols in Revision 15 protocols foundProtocols under revision.Acalabrutinib 100, Marginal Zone Lymphoma (PID2402 V1.0)Bortezomib 1.3 / Rituximab 375 / Bendamustine 90, indolent B-Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID2678 V1.0)Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334 V1.0)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308 V1.2)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 Maintenance, follicular lymphoma °I-IIIa (PID725 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1 (PID710 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6 (PID724 V1.0)Obinutuzumab 1000, B-non-Hodgkin Lymphoma, maintenance (PID2341 V1.0)Obinutuzumab 1000, B-Non-Hodgkin Lymphoma, Induction (PID2340 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270 V1.0)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329 V1.0)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309 V1.0)Zanubrutinib 160, marginal zone lymphoma (PID2227 V1.1)
